Ballentine Partners, LLC Intellia Therapeutics, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 17,120 shares of NTLA stock, worth $216,054. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,120
Previous 17,120
-0.0%
Holding current value
$216,054
Previous $160,000
84.38%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
341Shares Held
97.1MCall Options Held
1.66MPut Options Held
1.05M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$164 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$137 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$121 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$52 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$51 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $959M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...